STAT+: Pharmalittle: FDA rejects Lilly application for Alzheimer’s drug; Sanofi offers a warranty for a medicine

And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is still in the works. For now, we expect to engage in our usual ritual of promenading with the official mascot, take a drive in the countryside with the radio turned up, and hold another listening party with Mrs. Pharmalot (the rotation will start with this and this). And what about you? This may be a fine time to indulge in a new round of binge-watching on the telly, or you could catch up on your reading. You could challenge friends to play a round of fun facts (did you know on this day in history, George Santos attended FDR’s second inauguration?). Or you could simply take stock of your life. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon. …

The U.S. Food and Drug Administration rejected an Eli Lilly application seeking accelerated approval for donanemab, a treatment for people with early stage Alzheimer’s disease, STAT notes. But Lilly said a planned readout from an ongoing, Phase 3 study of the drug remains on track for the middle of the year, and if positive, will form the basis of an application for full approval “shortly thereafter.” Lilly filed for accelerated approval based on a mid-stage study that showed the drug lowered levels of amyloid. But the FDA rejected the application because the study did not include enough patients who had taken the medicine for at least a year.

Continue to STAT+ to read the full story…